CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 12 enrolled
Drug / intervention
Mechlorethamine 0.016% Top Geldrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03417141
NCT03417141Phase 2Completed
CompareCT.gov

Valchlor in the Treatment of Lichen Planopilaris: A Single Arm, Open- Label, Exploratory Study

Mayo Clinic·interventional·Posted Jan 31, 2018·Updated Jan 28, 2021

In Brief

A Phase 2 clinical trial evaluating Mechlorethamine 0.016% Top Gel for Lichen Planopilaris. Completed, enrolled 12 participants across 1 site.

Detailed Summary

The primary objective of this study is to assess the potential effectiveness of once daily application of Valchlor in decreasing disease activity in patients with Lichen Planopilaris. The primary measurement of efficacy will be with the Lichen Planopilaris Activity Index (LPPAI) before and after 6 months of treatment. Secondary measures of efficacy will be the mean follicular density, Physician Global assessment (PGA) score, and the Dermatology Quality of Life Index (DQLI) score before and after six months of therapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLichen Planopilaris
CountriesUnited States
CollaboratorsActelion

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedJan 31, 2018
Enrollment StartApr 1, 2018
Primary CompletionAug 30, 2019
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 8.4 years ago

Interventions

Mechlorethamine 0.016% Top Geldrug

Valchlor, a 0.016% gel formulation of mechlorethamine. Once daily application of Valchlor in decreasing disease activity in patients with Lichen Planopilaris.